Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMN5T2A)

Drug Name
Ciclopirox Drug Info
Synonyms
Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
2749
ChEBI ID
CHEMBL1413
CAS Number
CAS 29342-05-0
TTD Drug ID
D07GRH
VARIDT Drug ID
DR00986
ACDINA Drug ID
D00945

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
HIF-1 signaling pathway 2.28 0.00e+0 105/109 (96.33%) ENO2;VEGFA;ALDOC;...
p53 signaling pathway 2.07 0.00e+0 63/73 (86.3%) IGFBP3;CDKN1A;TNFRSF10B;...
PI3K-Akt signaling pathway 2.04 0.00e+0 317/354 (89.55%) VEGFA;CDKN1A;LAMA3;...
ECM-receptor interaction 2.04 0.00e+0 80/88 (90.91%) LAMA3;FN1;LAMB3;...
Central carbon metabolism in cancer 2.03 0.00e+0 67/70 (95.71%) SLC2A1;PFKP;PGAM1;...
Thyroid cancer 2.01 0.00e+0 36/37 (97.3%) CDKN1A;DDB2;PPARG;...
Starch and sucrose metabolism 2.01 0.00e+0 25/36 (69.44%) HK2;GBE1;GYS1;...
Glycolysis / Gluconeogenesis 1.97 0.00e+0 56/67 (83.58%) ENO2;ALDOC;PFKP;...
Focal adhesion 1.97 0.00e+0 180/201 (89.55%) VEGFA;LAMA3;FN1;...
Arrhythmogenic right ventricular cardiomyopathy 1.93 1.19e-3 70/77 (90.91%) ITGA5;CDH2;ITGA3;...
Small cell lung cancer 1.91 5.40e-3 90/92 (97.83%) CDKN1A;LAMA3;FN1;...
Bacterial invasion of epithelial cells 1.91 4.95e-3 59/77 (76.62%) FN1;CAV1;ITGA5;...
Bladder cancer 1.90 4.57e-3 40/41 (97.56%) VEGFA;CDKN1A;EGFR;...
Fructose and mannose metabolism 1.86 7.64e-3 30/33 (90.91%) ALDOC;PFKP;PFKFB3;...
Renal cell carcinoma 1.86 7.13e-3 68/69 (98.55%) VEGFA;CDKN1A;SLC2A1;...
Proteoglycans in cancer 1.84 8.17e-3 172/205 (83.9%) VEGFA;CDKN1A;FN1;...
Endometrial cancer 1.80 1.47e-2 56/58 (96.55%) CDKN1A;EGFR;DDB2;...
Pancreatic cancer 1.78 1.91e-2 75/76 (98.68%) VEGFA;CDKN1A;TGFA;...
Glycine, serine and threonine metabolism 1.77 2.06e-2 31/40 (77.5%) PGAM1;MAOA;CTH;...
Fluid shear stress and atherosclerosis 1.77 1.96e-2 123/139 (88.49%) VEGFA;CAV1;DUSP1;...
Human papillomavirus infection 1.77 1.92e-2 284/331 (85.8%) VEGFA;CDKN1A;LAMA3;...
Parathyroid hormone synthesis, secretion and action 1.76 1.89e-2 98/106 (92.45%) CDKN1A;EGFR;PTHLH;...
Glucagon signaling pathway 1.75 2.02e-2 89/107 (83.18%) SLC2A1;PFKP;PGAM1;...
Glioma 1.71 2.58e-2 67/75 (89.33%) CDKN1A;TGFA;EGFR;...
Oxytocin signaling pathway 1.71 2.52e-2 128/154 (83.12%) CDKN1A;EGFR;OXTR;...
Glycosaminoglycan degradation 1.71 2.47e-2 19/19 (100%) HEXB;HGSNAT;GNS;...
Alcoholism 1.71 2.38e-2 86/186 (46.24%) NTRK2;MAOA;NPY;...
Prostate cancer 1.69 2.59e-2 93/97 (95.88%) CDKN1A;TGFA;EGFR;...
MicroRNAs in cancer 1.69 2.62e-2 146/310 (47.1%) VEGFA;CDKN1A;DDIT4;...
Bile secretion 1.69 2.58e-2 68/90 (75.56%) SLC2A1;CA2;UGT2B28;...
RNA polymerase -1.75 1.82e-2 23/31 (74.19%) POLR3F;POLR2K;POLR2B;...
RNA transport -1.91 1.78e-3 128/186 (68.82%) SAP18;GLE1;PAIP1;...
Staphylococcus aureus infection -1.95 1.02e-3 72/95 (75.79%) DEFA5;HLA-DMB;FCGR3B;...
Ribosome -1.97 1.19e-3 113/158 (71.52%) FAU;RPL6;RPL36A;...
Asthma -1.99 1.43e-3 25/31 (80.65%) CCL11;TNF;HLA-DMB;...
Systemic lupus erythematosus -2.05 1.78e-3 45/135 (33.33%) ELANE;CTSG;IL10;...
Spliceosome -2.26 0.00e+0 101/150 (67.33%) SRSF1;DHX38;TCERG1;...
Proteasome -2.29 0.00e+0 44/46 (95.65%) PSMB2;PSMB7;PSMA6;...
Ribosome biogenesis in eukaryotes -2.41 0.00e+0 52/108 (48.15%) MPHOSPH10;POP1;RCL1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 24H